Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sphenopalatine Block vs BOTOX in Chronic Migraine
NCT06974617Recruiting
- Sponsor
- Cairo University
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of lidocaine 10% oropharyngeal spray in chronic migraine (2 arms), sponsored by Cairo University. Primary endpoint: Degree of pain at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT06974617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974617.